Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
Milí naši čitatelia,
17 decembra, 2020 4:56 pmdostáva sa k vám ďalšie číslo plné nových informácií o problematike sclerosis multiplex (SM). Súčasnosť je nesmierne dramatická a všetci zažívame veľkú globálnu...
POMALIDOMID IS MORE EFFECTIVE IN REAL CLINICAL PRACTICE THAN IN RANDOMIZED TRIAL – AN OBSERVATIONAL STUDY OF THE CZECH MYELOMA GROUP
15 októbra, 2020 7:26 pmAuthor(s): Ludek Pour, Lucie Brozova, Ivan Spicka, et. al. Abstract: S 1290 Session topic: 14. Myeloma and other...
LENALIDOMIDE INDUCTION AND MAINTENANCE THERAPY FOR TRANSPLANT ELIGIBLE MYELOMA PATIENTS: RESULTS OF THE MYELOMA XI STUDY
15 októbra, 2020 7:26 pmAuthor(s): Charlotte Pawlyn, Faith Davies, David Cairns, et. al. Abstract: S 781 Session topic: 14. Myeloma and other...
MINIMAL RESIDUAL DISEASE (MRD) BY MULTIPARAMETER FLOW CYTOMETRY (MFC) IN TRANSPLANT ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM): RESULTS FROM THE EMN02/HO95 PHASE 3 TRIAL
15 októbra, 2020 7:26 pmAuthor(s): Stefania Oliva, Davine Hofste op Bruinink, Lucie Říhová, et. al. Abstract: S 102 Session topic: 13. Myeloma...
EFFICACY BY CYTOGENETIC RISK STATUS FOR DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE OR BORTEZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
15 októbra, 2020 7:26 pmAuthor(s): Jesus San-Miguel, Katja Weisel, Gordon Cook, et. al. Abstract: S 101 Session topic: 14. Myeloma and other...
MNOHOPOČETNÝ MYELÓM
15 októbra, 2020 7:26 pmNa kongrese EHA 2017 bol mnohopočetnému myelómu (MM) venovaný značný priestor v rámci edukačného a satelitných sympózií, vedeckej pracovnej skupiny a taktiež v posterovej sekcii....
QUIZARTINIB (AC220) IN PATIENTS WITH FLT3-ITD(+) RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: FINAL RESULTS OF A RANDOMIZED PHASE 2 STUDY
15 októbra, 2020 7:26 pmAuthor(s): Nigel Russell, Martin S. Tallman, Stuart Goldberg, Abstract: ABSSUB-4757 Session topic: 4. Acute myeloid leukemia – Clinical...
ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO REQUIRE TWO COURSES OF INDUCTION THERAPY TO ACHIEVE COMPLETE REMISSION (CR) SHOULD UNDERGO ALLOGENEIC TRANSPLANT (ALLO-SCT) DURING THE FIRST CR
15 októbra, 2020 7:26 pmAuthor(s): Hiroaki Shimizu, Hiroshi Handa, Nahoko Hatsumi, et. al. Abstract: ABSSUB-4989 Session topic: 4. Acute myeloid leukemia –...
RESULTS OF A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF AZACITIDINE (AZA) VS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)
15 októbra, 2020 7:26 pmAuthor(s): Hervé Dombret, John F. Seymour, Aleksandra Butrym, et. al. Abstract: LB-6212 Session topic: 4. Acute myeloid leukemia...
VALIDATION OF EUROPEAN LEUKEMIA NET (ELN) GUIDELINES FOR CYTOGENETICALLY NORMAL AML IN ASSOCIATION WITH NPM1 AND FLT3-ITD MUTATIONS: FURTHER STRATIFICATION FOCUSING ON WT1 EXPRESSION
15 októbra, 2020 7:26 pmAuthor(s): Jae-Ho Yoon, Hee-Je Kim, Young-Woo Jeon, et. al. Abstract: ABSSUB-3999 Session topic: 4. Acute myeloid leukemia –...